Hematology/Oncology Clinics of North America This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Waldenstr öm Macroglobulinemia
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 28, 2023 Category: Cancer & Oncology Authors: Jorge J. Castillo, Shayna Sarosiek, Prashant Kapoor Source Type: research

Copyright
ELSEVIER (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 28, 2023 Category: Cancer & Oncology Source Type: research

Contributors
GEORGE P. CANELLOS, MD (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 28, 2023 Category: Cancer & Oncology Source Type: research

Contents
Jorge J. Castillo, Shayna Sarosiek, and Prashant Kapoor (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 28, 2023 Category: Cancer & Oncology Source Type: research

Forthcoming Issues
Renal Cell Cancer (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 28, 2023 Category: Cancer & Oncology Source Type: research

Novel Immune Therapies for Renal Cell Carcinoma
Immunotherapy has revolutionized treatment for patients with advanced and metastatic renal cell carcinoma. Nevertheless, many patients do not benefit or eventually relapse, highlighting the need for novel immune targets to overcome primary and acquired resistance. This review discusses 2 strategies currently being investigated: disabling inhibitory stimuli that maintain immunosuppression ( “brakes”) and priming the immune system to target tumoral cells (“gas pedals”). We explore each class of novel immunotherapy, including the rationale behind it, supporting preclinical and clinical evidence, and limitations. (Sour...
Source: Hematology/Oncology Clinics of North America - June 28, 2023 Category: Cancer & Oncology Authors: Eddy Saad, Ren ée Maria Saliby, Chris Labaki, Wenxin Xu, Srinivas R. Viswanathan, David A. Braun, Ziad Bakouny Source Type: research

Novel Targeted Therapies for Renal Cell Carcinoma
Targeted therapies have revolutionized the treatment of renal cell carcinoma (RCC). The VHL/HIF pathway is responsible for the regulation of oxygen homeostasis and is frequently altered in RCC. Targeting this pathway as well as the mTOR pathway have yielded remarkable advances in the treatment of RCC. Here, we review the most promising novel targeted therapies for the treatment of RCC, including HIF2 α, MET, metabolic targeting, and epigenomic reprogramming. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 27, 2023 Category: Cancer & Oncology Authors: Ren ée Maria Saliby, Eddy Saad, Chris Labaki, Wenxin Xu, David A. Braun, Srinivas R. Viswanathan, Ziad Bakouny Source Type: research

Lung Cancer and Lifestyle Factors
This review explores the effect of common everyday factors, such as alcohol, tea and coffee consumption, on the risk for lung cancer. We performed an umbrella review of current systematic reviews. The risk for lung cancer was increased with alcohol or coffee intake and decreased with tea intake. While evidence for alcohol is of low quality, the effect of coffee may be confounded by the smoking effect. The protective effect of tea intake is present, but the evidence is also of low quality. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 25, 2023 Category: Cancer & Oncology Authors: Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha Source Type: research

Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
In locally advanced RCC, 6 phase 3 randomized controlled trials (RCTs) were designed in the perioperative setting with immune checkpoint inhibitor (ICI) monotherapy or combinations. Adjuvant trials with atezolizumab, pembrolizumab, and nivolumab with ipilimumab reported results, as did the only perioperative trial with nivolumab. Of these, only 1  year of adjuvant pembrolizumab improved disease-free survival (DFS) versus placebo, with the other trials showing no improvement in DFS. In the purely neoadjuvant setting, phase 1 b/2 ICI trials have demonstrated safety, efficacy, and dynamic changes of immune infiltrates, and ...
Source: Hematology/Oncology Clinics of North America - June 25, 2023 Category: Cancer & Oncology Authors: Teele Kuusk, Axel Bex Source Type: research

Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
The authors review the current use of chimeric antigen receptor (CAR)-transduced T  cells (CAR-T) in Hodgkin lymphoma (HL) and T-cell lymphomas (TCL) and discuss the data on CD30-targeting CAR-T cells, which seem to be safe and effective in HL. In addition, the authors examine the use of CAR-T cells targeting CD30, CD5, or CD7 in TCL, while highlighting the unique challenges of t heir use in this subset of lymphomas. Furthermore, the authors present future directions and ongoing trials investigating the use of CAR-T cells in TCL and HL. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 23, 2023 Category: Cancer & Oncology Authors: Ibrahim N. Muhsen, LaQuisa C. Hill, Carlos A. Ramos Source Type: research

Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
Treatment of metastatic renal cell carcinoma (mRCC) after first-line immune checkpoint inhibitors (ICIs) lacks standardization, with limited evidence from small trials and retrospective data. Vascular endothelial growth factor receptor (VEGFR) inhibition through tyrosine kinase inhibitors (TKIs) is the most widely adopted second-line treatment. Encouraging results have been seen with VEGFR-TKIs in the second-line after exposure to an ICI-based combination, achieving a response rate of 30%, and 75% of patients achieving disease control. Rechallenge with ICI alone seems safe but has limited clinical benefit. Promising regime...
Source: Hematology/Oncology Clinics of North America - June 21, 2023 Category: Cancer & Oncology Authors: Regina Barragan-Carrillo, Ameish Govindarajan, Adam Rock, Rubens C. Sperandio, Sumanta K. Pal Source Type: research

Toxicity Management of Systemic Kidney Cancer Therapies
Systemic treatments for metastatic renal cell carcinoma have expanded to include antiangiogenic agents targeting either vascular endothelial growth factor receptor, immune checkpoint inhibitors against cytotoxic T-lymphocyte antigen 4, or programmed cell death 1 pathways, and combinations of these treatments. The hypoxia inducible factor-2 inhibitors are emerging, whereas mammalian target of rapamycin (inhibitors) role is fading. To sustain optimal efficacy of these agents, potential toxicities must be recognized early and clinically managed. Here, the authors discuss the adverse events attributable to these treatments and...
Source: Hematology/Oncology Clinics of North America - June 21, 2023 Category: Cancer & Oncology Authors: Qian Qin, Ellen Nein, Andrea Flaten, Tian Zhang Source Type: research

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
We describe challenges including physical and molecular barriers to trafficking CAR-Ts, an immunosuppressive tumor microenvironment, and difficulty finding cell surface target antigens. The application of new approaches in synthetic biology and cellular engineering toward solid tumor CAR-Ts is described. Finally, we summarize reported and ongoing clinical trials of CAR-T therapies for select disease sites such as head and neck (including thyroid cancer), lung, central nervous system (glioblastoma, neuroblastoma, glioma), sarcoma, genitourinary (prostate, renal, bladder, kidney), breast and ovarian cancer. (Source: Hematolo...
Source: Hematology/Oncology Clinics of North America - June 21, 2023 Category: Cancer & Oncology Authors: Jeremiah A. Wala, Glenn J. Hanna Source Type: research

Early and Late Toxicities of Chimeric Antigen Receptor T-Cells
As chimeric antigen receptor (CAR) T-cell therapy is increasingly integrated into clinical practice across a range of malignancies, identifying and treating inflammatory toxicities will be vital to success. Early experiences with CD19-targeted CAR T-cell therapy identified cytokine release syndrome and neurotoxicity as key acute toxicities and led to unified initiatives to mitigate the influence of these complications. In this section, we provide an update on the current state of CAR T-cell-related toxicities, with an emphasis on emerging acute toxicities affecting additional organ systems and considerations for delayed to...
Source: Hematology/Oncology Clinics of North America - June 21, 2023 Category: Cancer & Oncology Authors: Rebecca Epperly, Victoria M. Giordani, Lekha Mikkilineni, Nirali N. Shah Source Type: research

State of Cancer Control in South America
Cancer is a major public health problem in South America. The cancer mortality burden is increasing in the region due to its presentation at later stages, which is related to limited access to cancer care. This results in a noticeable inequity in provisions of cancer care including specialized screening programs, as well as cancer-related treatments such as personalized medicine, radiation therapy, palliative care, and survivorship services. Consequently, South America faces many challenges for cancer control, most of them deriving from a lack of funding and unequal distribution of resources and cancer services, affecting ...
Source: Hematology/Oncology Clinics of North America - June 21, 2023 Category: Cancer & Oncology Authors: Ivy Riano, Ana I. Velazquez, Lucia Viola, Inas Abuali, Kathya Jimenez, Oyepeju Abioye, Narjust Florez Source Type: research